A detailed history of Lazard Asset Management LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Lazard Asset Management LLC holds 6,579 shares of BMRN stock, worth $438,358. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,579
Previous 256 2469.92%
Holding current value
$438,358
Previous $21,000 2100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$69.02 - $93.84 $436,413 - $593,350
6,323 Added 2469.92%
6,579 $462,000
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $38,554 - $47,769
-518 Reduced 66.93%
256 $21,000
Q1 2024

May 14, 2024

SELL
$83.81 - $99.0 $17,767 - $20,988
-212 Reduced 21.5%
774 $66,000
Q4 2023

Feb 14, 2024

BUY
$76.22 - $98.51 $3,048 - $3,940
40 Added 4.23%
986 $95,000
Q3 2023

Nov 14, 2023

BUY
$85.07 - $94.48 $3,572 - $3,968
42 Added 4.65%
946 $83,000
Q2 2023

Aug 14, 2023

SELL
$86.68 - $100.3 $293,585 - $339,716
-3,387 Reduced 78.93%
904 $78,000
Q1 2023

May 15, 2023

BUY
$87.74 - $117.27 $308,055 - $411,734
3,511 Added 450.13%
4,291 $416,000
Q4 2022

Feb 14, 2023

SELL
$80.93 - $108.63 $103,509 - $138,937
-1,279 Reduced 62.12%
780 $80,000
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $82 - $96
1 Added 0.05%
2,059 $174,000
Q2 2022

Aug 09, 2022

BUY
$71.48 - $86.85 $5,146 - $6,253
72 Added 3.63%
2,058 $169,000
Q1 2022

May 13, 2022

SELL
$74.28 - $92.69 $24,586 - $30,680
-331 Reduced 14.29%
1,986 $153,000
Q4 2021

Feb 09, 2022

BUY
$71.72 - $91.47 $58,164 - $74,182
811 Added 53.85%
2,317 $204,000
Q3 2021

Nov 15, 2021

SELL
$74.77 - $85.47 $42,544 - $48,632
-569 Reduced 27.42%
1,506 $116,000
Q2 2021

Aug 12, 2021

SELL
$75.51 - $84.79 $388,498 - $436,244
-5,145 Reduced 71.26%
2,075 $172,000
Q1 2021

May 14, 2021

BUY
$74.73 - $90.69 $537,009 - $651,698
7,186 Added 21135.29%
7,220 $545,000
Q4 2020

Feb 11, 2021

BUY
$72.61 - $90.2 $2,468 - $3,066
34 New
34 $2,000
Q2 2020

Aug 13, 2020

SELL
$79.55 - $124.22 $1.25 Million - $1.95 Million
-15,691 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$71.37 - $96.85 $1.11 Million - $1.51 Million
15,587 Added 14987.5%
15,691 $1.33 Million
Q4 2019

Feb 13, 2020

BUY
$64.27 - $86.37 $6,684 - $8,982
104 New
104 $8,000
Q3 2018

Nov 13, 2018

SELL
$93.92 - $105.72 $1.73 Million - $1.95 Million
-18,427 Closed
0 $0
Q2 2018

Aug 13, 2018

BUY
$76.01 - $99.03 $823,644 - $1.07 Million
10,836 Added 142.75%
18,427 $1.74 Million
Q1 2018

May 14, 2018

SELL
$77.67 - $92.63 $134,136 - $159,972
-1,727 Reduced 18.53%
7,591 $615,000
Q4 2017

Feb 13, 2018

SELL
$80.76 - $95.13 $275,956 - $325,059
-3,417 Reduced 26.83%
9,318 $830,000
Q3 2017

Aug 19, 2019

BUY
$80.6 - $94.95 $3,385 - $3,987
42 Added 0.33%
12,735 $1.18 Million
Q3 2017

Nov 13, 2017

SELL
$80.6 - $94.95 $320,949 - $378,090
-3,982 Reduced 23.88%
12,693 $1.18 Million
Q2 2017

Aug 19, 2019

SELL
N/A
-3,426 Reduced 17.04%
16,675 $1.51 Million
Q1 2017

Aug 13, 2019

SELL
N/A
-10,847 Reduced 35.05%
20,101 $1.76 Million
Q4 2016

Jul 30, 2019

SELL
N/A
-12,433 Reduced 28.66%
30,948 $2.56 Million
Q3 2016

Aug 07, 2019

BUY
N/A
7,762 Added 21.79%
43,381 $4.01 Million
Q2 2016

Jul 29, 2019

BUY
N/A
35,619
35,619 $2.77 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.